Cadence Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Cadence Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-726	Closed	-$958K	–	595
2015 Q2	$958K	Buy	726 +315	+77%	+$361K	0.05%	436
2015 Q1	$427K	Buy	+411	New	+$272K	0.03%	523

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Cadence Capital Management's ATRA Position: Q3 2015 in Review

Cadence Capital Management sold out of Atara Biotherapeutics (ATRA) in Q3 2015, closing a stake of 726 shares — an estimated $958K sold.

Cadence Capital Management first reported a position in ATRA in Q1 2015 and held it in 2 quarters. The position peaked at $958K in Q2 2015. 91 funds tracked by Wall St. Rank hold ATRA as of Q3 2015.

Cadence Capital Management reported no remaining Atara Biotherapeutics position as of Q3 2015 after selling out during the quarter.
Cadence Capital Management sold 726 Atara Biotherapeutics shares in Q3 2015, an estimated $958K.
Cadence Capital Management first reported a position in Atara Biotherapeutics in Q1 2015 and held it in 2 quarters.
Cadence Capital Management's Atara Biotherapeutics position peaked at $958K in Q2 2015.
91 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2015.

Based on Cadence Capital Management's 13F filing for Q3 2015, filed 12 Nov 2015.